aTyr Pharma (ATYR) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
aTyr Pharma, Inc. (ATYR) specializes in therapies for rare pulmonary pathologies, creating stable demand for its unique developments. The innovative mechanism of action of its drugs protects the business from the pressure of cheap generics. The company also adheres to ESG principles, focusing on biosafety and trial ethics. This price chart on GURU.Markets shows that the EV/EBITDA ratio is 0.00, helping to assess the asset's value.
atyrpharma.com - analytical breakdowns and key metrics (ATYR)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity aTyr Pharma, Inc.|ATYR - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital aTyr Pharma|ATYR - Company Cumulative Debt|Debts to Book Capitalization aTyr Pharmaceuticals|ATYR - Company Long-Term Debts|Company Current Liabilities aTyr Pharma|Quick Liquidity Indicator atyrpharma.com
- business earnings and investment ratios data:
ATYR - Company Net Income|Expected Profit aTyr Pharma, Inc.|ATYR - Company Value to Net Income|Projected Price to Earnings aTyr Pharma, Inc.|ATYR - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aTyr Pharmaceuticals|ATYR - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) aTyr Pharma|ATYR - Earnings per share for the trailing year|Quarterly EPS earnings growth atyrpharma.com|ATYR - Earnings growth in current year|Net earnings per share growth forecast for next year aTyr Pharma, Inc.
Initial company analysis:aTyr ATYR
Investors must filter out market noise to assess the cost of capital for aTyr Pharma, Inc. (ATYR), given its minimal environmental footprint and strict adherence to laboratory protocols. By analyzing the EV/EBITDA ratio over a specific time interval, you determine the relationship between the total enterprise value and operating profit before interest, taxes, depreciation, and amortization, which allows for the identification of overpayment risks and confirms the fundamental stability of the biotech business.
Competitors of aTyr Pharma, Inc.
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|DNTH - EV/EBITDA Multiple|PHVS (Pharvaris N.V.) - Enterprise Value to EBITDA Ratio|ABCL: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TRML|Company Value to EBITDA Precigen Inc PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|Upstream Bio Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ZBIO|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GOSS|KALV: EV/EBITDA Multiple|Septerna Pharma - Business Value to Operating Income Before Depreciation|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|EV/EBITDA Multiple savarapharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|ENGN - Enterprise Value to EBITDA Ratio|RAPT Therapeutics - EV/EBITDA Multiple|JBIO - EV/EBITDA Multiple|ACRS (Aclaris Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Kyverna Therapeutics Inc. - Business Value to Operating Income Before Depreciation|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Cabaletta Bio Inc (CABA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ventyx Biosciences (VTYX)|theratech.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|ELDN - Enterprise Value to EBITDA Ratio|AGEN: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Climb Bio, Inc CLYM|ZURA: EV/EBITDA Multiple|Adagene Inc. (ADAG) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio IMA|STTK (Shattuck Therapeutics) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio EQ (Equillium, Inc.)|CNTB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic IMUX|Business Value to Operating Income Before Depreciation ATRA|IFRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XFOR|ACET: EV/EBITDA Multiple|Celularity - Business Value to Operating Income Before Depreciation|INMB (INmune Bio, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple barinthusbio.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kezar Life Sciences, Inc. (KZR)|SABS (SAB Biotherapeutics Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|ENLV - Enterprise Value to EBITDA Ratio|Q32 Bio Corp - EV/EBITDA Multiple|GOVX - EV/EBITDA Multiple|EDSA (Edesa Biotech) - Enterprise Value to EBITDA Ratio|iBio Inc - Business Value to Operating Income Before Depreciation|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|XTL Bio (XTLB) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics (BOLT)|Enterprise Value to EBITDA Ratio hcwbiologics.com HCWB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|AIM - Enterprise Value to EBITDA Ratio|ADTX: Enterprise Value to EBITDA Ratio|GRI - EV/EBITDA Multiple|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation HIND|REVB (Revelation Biosciences, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Indaptus Therapeutics Inc INDP|EV/EBITDA Multiple SCNI|EV/EBITDA Multiple calcimedica.com (CALI)|Affimed N.V. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ALLK (Allakos Inc)|HOOK: Enterprise Value to EBITDA Ratio|Company Value to EBITDA IGM Biosciences, Inc.|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Ocean Biomedical Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TCBP|THRD: Business Value to Operating Income Before Depreciation
